Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

Olalekan O. Oluwole, Sally W. Wade, Nathaniel J Smith, Tomas Spousta, Jenny J. Kim, Yan Zheng, Timothy Best, Markqayne Ray, Lori A. Leslie

Blood (2024) 144 (Supplement 1): 7607.

https://doi.org/10.1182/blood-2024-206879

Published: 2024

Journal Articles

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Jyoti Arora, Sabarish Ayyappan, Chaobo Yin, Brian J. Smith, Caitlin D. Lemke-Miltner, Zhaoming Wang, Umar Farooq, George J. Weiner

Blood (2024) 143 (18): 1816–1824.

https://doi.org/10.1182/blood.2023023370

Published: 2024

Includes: Supplemental data

Journal Articles

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Anik R Patel, Mark Ray, Yael A Rodriguez-Guadarrama, Nathaniel J Smith, Frank Neumann, Rob Blisset, Allen Xiaodong Xue

Blood (2023) 142 (Supplement 1): 6899.

https://doi.org/10.1182/blood-2023-181255

Published: 2023

Journal Articles

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Blood (2022) 140 (Supplement 1): 1413–1415.

https://doi.org/10.1182/blood-2022-156921

Published: 2022

Journal Articles

Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models

Kieron South, Ohud Saleh, Eloise Lemarchand, Graham Coutts, Craig J. Smith, Ingo Schiessl, Stuart M. Allan

Blood (2022) 139 (10): 1575–1587.

https://doi.org/10.1182/blood.2021012787

Published: 2022

Includes: Supplemental data

Journal Articles

A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015

Caleb J. Smith, MD, Gordon J. Ruan, MD, John William Thomas, Ayalew Tefferi, MD, Ronald S. Go, MD, Guarav Goyal, Mithun Vinod Shah, MD PhD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-137611

Published: 2020

Journal Articles

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Gordon Ruan, MD, Caleb J. Smith, MD, Courtney Day, William Harmsen, Abhishek A. Mangaonkar, MBBS, Hassan B. Alkhateeb, MD, Kebede H. Begna, MD, Aref Al-Kali, MD, Mark Litzow, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Michelle A Elliott, MD, Ayalew Tefferi, MD, Ronald S. Go, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136350

Published: 2020

Journal Articles

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Blood (2019) 134 (Supplement_1): 1610.

https://doi.org/10.1182/blood-2019-126068

Published: 2019

Journal Articles

Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation

Michael J Thomenius, PhD BA, Jennifer Totman, Kat Cosmopoulos, Dorothy Brach, Lei Ci, Neil Farrow, Jesse J Smith, Richard Chesworth, Kenneth W. Duncan, Cuyue Tang, Thomas Riera, John Lampe

Blood (2018) 132 (Supplement 1): 3207.

https://doi.org/10.1182/blood-2018-99-110803

Published: 2018

Journal Articles

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Blood (2018) 132 (12): 1225–1240.

https://doi.org/10.1182/blood-2018-04-843771

Published: 2018

Includes: Supplemental data

Journal Articles

Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor

Blood (2017) 130 (Supplement 1): 537.

https://doi.org/10.1182/blood.V130.Suppl_1.537.537

Published: 2017

Journal Articles

Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD

Benjamin M. Matta, Dawn K. Reichenbach, Xiaoli Zhang, Lisa Mathews, Brent H. Koehn, Gaelen K. Dwyer, Jeremy M. Lott, Franziska M. Uhl, Dietmar Pfeifer, Colby J. Feser, Michelle J. Smith, Quan Liu, Robert Zeiser, Bruce R. Blazar, Hēth R. Turnquist

Blood (2016) 128 (3): 427–439.

https://doi.org/10.1182/blood-2015-12-684142

Published: 2016

Includes: Supplemental data

Journal Articles

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Blood (2014) 124 (21): 438.

https://doi.org/10.1182/blood.V124.21.438.438

Published: 2014

Journal Articles

Aberration Of SF3B1 Results In Deregulated Splicing Of Key Genes and Pathways In Myelodysplastic Syndromes

Hamid Dolatshad, PhD, Marta Fernandez-Mercado, PhD, Bon Ham Yip, PhD, Chris J Smith, PhD, Martin Attwood, BSc, MRes, Cristina Di Genua, BSc, Natasha Sahgal, PhD, Bartlomiej P Przychodzen, PhD, Elli Papaemmanuil, PhD, Alexander A Kanapin, PhD, Helen Lockstone, PhD, Peter J. Campbell, PhD, Jaroslaw P. Maciejewski, MD, PhD, Andrea Pellagatti, PhD, Jacqueline Boultwood

Blood (2013) 122 (21): 2747.

https://doi.org/10.1182/blood.V122.21.2747.2747

Published: 2013

Journal Articles

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models

L. Danielle Johnston, Sarah Knutson, PhD, Natalie Warholic, Christine R Klaus, Tim J. Wigle, PhD, Dorothy Iwanowicz, Bruce A. Littlefield, PhD, Margaret Porter Scott, PhD, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Roy M. Pollock, PhD, Kevin W Kuntz, PhD, Heike Keilhack, PhD, Alejandra Raimondi

Blood (2013) 122 (21): 4416.

https://doi.org/10.1182/blood.V122.21.4416.4416

Published: 2013

Journal Articles

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL -Rearranged Leukemia Cells

Christine R Klaus, Scott R. Daigle, PhD, Dorothy Iwanowics, L. Danielle Johnston, Carly A Therkelsen, Jesse J Smith, PhD, Mikel P Moyer, PhD, Robert A. Copeland, PhD, Edward J Olhava, PhD, Margaret Porter Scott, PhD, Roy M. Pollock, PhD, Alejandra Raimondi

Blood (2013) 122 (21): 3930.

https://doi.org/10.1182/blood.V122.21.3930.3930

Published: 2013

Journal Articles

Cost-Effectiveness Of Thromboprophylaxis In Pregnant Women With Sickle Cell Disease

Afshan H. Rizvi, Kenneth J. Smith, MD, MS, Margaret V. Ragni

Blood (2013) 122 (21): 426.

https://doi.org/10.1182/blood.V122.21.426.426

Published: 2013

Journal Articles

Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

Shuju Feng, Stephen J. Eyler, Yuzhou Zhang, Tara Maga, Carla M. Nester, Michael H. Kroll, Richard J. Smith, Vahid Afshar-Kharghan

Blood (2013) 122 (8): 1487–1493.

https://doi.org/10.1182/blood-2013-03-492421

Published: 2013

Includes: Supplemental data

Journal Articles

Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.

Craig D. Seaman, MD, Margaret V. Ragni, MD, MPH, Kenneth J. Smith, MD, MS

Blood (2012) 120 (21): 3177.

https://doi.org/10.1182/blood.V120.21.3177.3177

Published: 2012

Journal Articles

Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide

Gisela Caceres, Joe Johnson, Kathy L. McGraw, Ashley A. Basiorka, Kenian Liu, Ph.D., Larry J Smith, Ph.D., F. Joseph Daugherty, MD, Sheng Wei, MD, Rami S. Komrokji, MD, Ling Zhang, MD, Neil Littleton, MD, Richard A. Wells, MD, DPhil, Lubomir Sokol, MD, Ph.D, Alan F List, MD

Blood (2012) 120 (21): 920.

https://doi.org/10.1182/blood.V120.21.920.920

Published: 2012

NARROW

Short-Term Costs Associated with Outpatient Use of Axicabtagene Ciloleucel in Second-Line Relapsed/Refractory Large B-Cell Lymphoma Based on Zuma-24 Clinical Trial

T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC

Statistical Challenges from Trials of Potentially Curative Treatments: Validation of Cure Assumptions When Analyzing Zuma-7 Follow-up Data of Axi-Cel and Standard of Care Therapy

Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Robust thrombolytic and anti-inflammatory action of a constitutively active ADAMTS13 variant in murine stroke models

A Population-Based Study of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis in the United States from 2001-2015

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database

Identification of a First-in-Class SETD2 Inhibitor That Shows Potent and Selective Anti-Proliferative Activity in t(4;14) Multiple Myeloma: T(4;14) Multiple Myeloma Cells Are Dependent on Both H3K36 Di and Tri-Methylation

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations

Reawakening of Human Fetal Hemoglobin and an Epigenetic Path to the Clinic for Sickle Cell Disease and Beta-Thalassemia: Identification of an Orally-Available, Potent, and Selective Euchromatic Histone Lysine Methyltransferase 1 and 2 (EHMT1/2) Inhibitor

Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD

Identification of a First-in-Class PRMT5 Inhibitor with Potent in Vitro and in Vivo Activity in Preclinical Models of Mantle Cell Lymphoma

Aberration Of SF3B1 Results In Deregulated Splicing Of Key Genes and Pathways In Myelodysplastic Syndromes

EZH2 Inhibitor EPZ-6438 Synergizes With Anti-Lymphoma Therapies In Preclinical Models

DOT1L Inhibitor EPZ-5676 Displays Synergistic Antiproliferative Activity in Combination with Standard of Care Drugs or DNA Hypomethylating Agents in MLL -Rearranged Leukemia Cells

Cost-Effectiveness Of Thromboprophylaxis In Pregnant Women With Sickle Cell Disease

Partial ADAMTS13 deficiency in atypical hemolytic uremic syndrome

Cost Effectiveness of Rivaroxaban Versus Warfarin for the Prevention of Recurrent Venous Thromboembolism.

Targeted Repression of TP53 Promotes Erythropoiesis in Del(5q) MDS and Overcomes Clinical Resistance to Lenalidomide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only